NEWS — PCI Biotech

NEWS

Posts by Ronny Skuggedal

PCI Biotech full year 2024 interim results

Ronny SkuggedalFebruary 27, 2025

Invitation to preliminary full-year 2024 results presentation

Ronny SkuggedalFebruary 25, 2025

PCI Biotech is recruiting a Scientist

Ronny SkuggedalFebruary 6, 2025

Employee share option scheme in connection with promotion of new CSO

Ronny SkuggedalJanuary 10, 2025

PCI Biotech is recruiting a new Senior Scientist position

Ronny SkuggedalSeptember 18, 2024

Employee share option scheme

Ronny SkuggedalSeptember 2, 2024

PCI Biotech first half 2024 interim results

Ronny SkuggedalAugust 28, 2024

Invitation to first half interim 2024 results presentation

Ronny SkuggedalAugust 23, 2024

Minutes of Annual General Meeting 2024

Ronny SkuggedalMay 24, 2024

Disclosure of voting rights for Chair of the Board

Ronny SkuggedalMay 23, 2024

Notice of Annual General Meeting 2024

Ronny SkuggedalMay 3, 2024

Annual Report 2023

Ronny SkuggedalApril 26, 2024

PCI Biotech second half 2023 interim report

Ronny SkuggedalFebruary 14, 2024

Invitation to second half interim 2023 results presentation

Ronny SkuggedalFebruary 12, 2024

PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing

Ronny SkuggedalOctober 13, 2023

European patent for mRNA delivery with fimaNAc

Ronny SkuggedalSeptember 7, 2023

PCI Biotech: Employee share option scheme

Ronny SkuggedalSeptember 4, 2023

Write-down of share capital registered

Ronny SkuggedalSeptember 1, 2023

PCI Biotech first half 2023 interim results

Ronny SkuggedalAugust 31, 2023

Invitation to first half interim 2023 results presentation

Ronny SkuggedalAugust 25, 2023